GlassScriptPhysician profile
Benjamin Louis Rosenfeld
NPI 1851820229
$1,740.95
in general payments reported to CMS, 2019-2025
20 companies · $707 in 2025
The $707 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $248 · 2022: $99.80 · 2023: $272 · 2024: $414 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,393.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $248.33 | 2021-2023 | Lifevest |
| Edwards Lifesciences Corporation | $212.16 | 2025 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $200.54 | 2021-2025 | Aveir, Thoratec Heartmate 3 Lvas Implant Kit |
| Amgen INC. | $183.48 | 2023-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $157.25 | 2024-2025 | |
| Pfizer INC. | $144.37 | 2023-2025 | |
| Biotronik INC. | $89.12 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $72.94 | 2023-2025 | Lokelma, Brilinta |
| Alnylam Pharmaceuticals INC. | $67.32 | 2024-2025 | Onpattro |
| Merck Sharp & Dohme LLC | $66.52 | 2024-2025 | Verquvo |
| Novo Nordisk INC | $65.83 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Inspire Medical Systems, INC. | $44.88 | 2024-2025 | Inspire |
| Daiichi Sankyo INC. | $42.38 | 2024 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $34.00 | 2024-2025 | Eliquis, Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $29.99 | 2024 | Arcalyst |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $21.32 | 2025 | Evkeeza |
| Lexicon Pharmaceuticals, INC. | $16.30 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.37 | 2025 | Jardiance |
| Medicomp INC | $14.83 | 2024 | Telepatch Cardiac Monitor |
| Kiniksa Pharmaceuticals, LTD. | $14.02 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Rosenfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.